133 related articles for article (PubMed ID: 25911381)
21. Acute kidney injury associated with smoking synthetic cannabinoid.
Buser GL; Gerona RR; Horowitz BZ; Vian KP; Troxell ML; Hendrickson RG; Houghton DC; Rozansky D; Su SW; Leman RF
Clin Toxicol (Phila); 2014 Aug; 52(7):664-73. PubMed ID: 25089722
[TBL] [Abstract][Full Text] [Related]
22. The detection of mephedrone (4-methylmethcathinone) in 4 fatalities in Scotland.
Torrance H; Cooper G
Forensic Sci Int; 2010 Oct; 202(1-3):e62-3. PubMed ID: 20685050
[No Abstract] [Full Text] [Related]
23. Identification and analytical characterization of the synthetic cathinone N-butylhexedrone.
Shevyrin V; Eltsov O; Shafran Y
Drug Test Anal; 2020 Jan; 12(1):159-163. PubMed ID: 31667946
[No Abstract] [Full Text] [Related]
24. Use of SPME-HS-GC-MS for the analysis of herbal products containing synthetic cannabinoids.
Cox AO; Daw RC; Mason MD; Grabenauer M; Pande PG; Davis KH; Wiley JL; Stout PR; Thomas BF; Huffman JW
J Anal Toxicol; 2012 Jun; 36(5):293-302. PubMed ID: 22582264
[TBL] [Abstract][Full Text] [Related]
25. Qualitative analysis of seized synthetic cannabinoids and synthetic cathinones by gas chromatography triple quadrupole tandem mass spectrometry.
Gwak S; Arroyo-Mora LE; Almirall JR
Drug Test Anal; 2015 Feb; 7(2):121-30. PubMed ID: 24827678
[TBL] [Abstract][Full Text] [Related]
26. A combined approach using transporter-flux assays and mass spectrometry to examine psychostimulant street drugs of unknown content.
Rosenauer R; Luf A; Holy M; Freissmuth M; Schmid R; Sitte HH
ACS Chem Neurosci; 2013 Jan; 4(1):182-90. PubMed ID: 23336057
[TBL] [Abstract][Full Text] [Related]
27. FAPA mass spectrometry of designer drugs.
Smoluch M; Gierczyk B; Reszke E; Babij M; Gotszalk T; Schroeder G; Silberring J
Talanta; 2016; 146():29-33. PubMed ID: 26695230
[TBL] [Abstract][Full Text] [Related]
28. Direct analysis in real time mass spectrometry with collision-induced dissociation for structural analysis of synthetic cannabinoids.
Musah RA; Domin MA; Cody RB; Lesiak AD; Dane AJ; Shepard JR
Rapid Commun Mass Spectrom; 2012 Oct; 26(19):2335-42. PubMed ID: 22956326
[TBL] [Abstract][Full Text] [Related]
29. Addressing the challenges in forensic drug chemistry.
Brandt SD; Kavanagh PV
Drug Test Anal; 2017 Mar; 9(3):342-346. PubMed ID: 28103651
[No Abstract] [Full Text] [Related]
30. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds.
Dresen S; Ferreirós N; Pütz M; Westphal F; Zimmermann R; Auwärter V
J Mass Spectrom; 2010 Oct; 45(10):1186-94. PubMed ID: 20857386
[TBL] [Abstract][Full Text] [Related]
31. The role of illicit, licit, and designer drugs in the traffic in Hungary.
Institóris L; Hidvégi E; Dobos A; Sija É; Kereszty ÉM; Tajti LB; Somogyi GP; Varga T
Forensic Sci Int; 2017 Jun; 275():234-241. PubMed ID: 28412575
[TBL] [Abstract][Full Text] [Related]
32. Assessment of types of synthetic cannabinoids in narcotic cases assessed by the Council of Forensic Medicine between 2011-2015, Ankara, Turkey.
Göl E; Çok İ
Forensic Sci Int; 2017 Nov; 280():124-129. PubMed ID: 29028489
[TBL] [Abstract][Full Text] [Related]
33.
Martek BA; Mihelač M; Gazvoda M; Virant M; Urankar D; Krivec M; Gostič T; Nemec B; Koštrun B; Janežič M; Klemenc S; Košmrlj J
Drug Test Anal; 2019 Apr; 11(4):617-625. PubMed ID: 30730110
[TBL] [Abstract][Full Text] [Related]
34. [Isomeric analysis of synthetic cannabinoids detected as designer drugs].
Uchiyama N; Kikura-Hanajiri R; Shoda T; Fukuhara K; Goda Y
Yakugaku Zasshi; 2011; 131(7):1141-7. PubMed ID: 21720146
[TBL] [Abstract][Full Text] [Related]
35. Synthetic cannabis.
Westin AA; Brede WR; Espnes KA
Tidsskr Nor Laegeforen; 2012 Oct; 132(20):2289. PubMed ID: 23736197
[No Abstract] [Full Text] [Related]
36. Identification and quantification of synthetic cannabinoids in 'spice-like' herbal mixtures: a snapshot of the German situation in the autumn of 2012.
Langer N; Lindigkeit R; Schiebel HM; Ernst L; Beuerle T
Drug Test Anal; 2014; 6(1-2):59-71. PubMed ID: 23723183
[TBL] [Abstract][Full Text] [Related]
37. Identification and analytical characterization of four synthetic cannabinoids ADB-BICA, NNL-1, NNL-2, and PPA(N)-2201.
Qian Z; Jia W; Li T; Hua Z; Liu C
Drug Test Anal; 2017 Jan; 9(1):51-60. PubMed ID: 27239006
[TBL] [Abstract][Full Text] [Related]
38. Qualitative Analysis and Detection of the Pyrolytic Products of JWH-018 and 11 Additional Synthetic Cannabinoids in the Presence of Common Herbal Smoking Substrates.
Raso S; Bell S
J Anal Toxicol; 2017 Jul; 41(6):551-558. PubMed ID: 28637216
[TBL] [Abstract][Full Text] [Related]
39. Resolution of isomeric new designer stimulants using gas chromatography - Vacuum ultraviolet spectroscopy and theoretical computations.
Skultety L; Frycak P; Qiu C; Smuts J; Shear-Laude L; Lemr K; Mao JX; Kroll P; Schug KA; Szewczak A; Vaught C; Lurie I; Havlicek V
Anal Chim Acta; 2017 Jun; 971():55-67. PubMed ID: 28456284
[TBL] [Abstract][Full Text] [Related]
40. "Not for human consumption": a review of emerging designer drugs.
Musselman ME; Hampton JP
Pharmacotherapy; 2014 Jul; 34(7):745-57. PubMed ID: 24710806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
